1  that associating CRAC channel inhibitors or hypocalcemic agents with rituximab may improve the treat

2 g receptor has improved our understanding of hypocalcemic and hypercalcemic conditions.

3 absent in the PD mice, such that paradoxical hypocalcemic and hyperphosphatemic responses were observ

4                             Bumed sheep were hypocalcemic and hypomagnesemic compared with sham-burne

5 g been examined by using vitamin D-deficient hypocalcemic animals.

6                                  They become hypocalcemic at 21 days of age, at which time their para

7 3)) 1alpha-hydroxylase (1alpha(OH)ase) under hypocalcemic conditions, previous studies showed that ca

8 n compared with the 2- to 3-fold increase in hypocalcemic controls.

9 ogical inhibitors, or reducing calcemia with hypocalcemic drugs sensitized human B lymphoma cell line

10 s a 32-residue peptide hormone known for its hypocalcemic effect and its inhibition of bone resorptio

11         We have recently reported the potent hypocalcemic effects of side-chain lactam-bridged analog

12 odimeric glycoprotein, first identified as a hypocalcemic hormone important for maintaining calcium h

13 nds resulting in T cell-mediated deficiency, hypocalcemic hypoparathyroidism, and conotruncal cardiac

14 morphic facies, conotruncal cardiac defects, hypocalcemic hypoparathyroidism, T-cell mediated immune

15  may be at risk for the later development of hypocalcemic hypoparathyroidism.

16                                              Hypocalcemic patients had a higher median baseline hemat

17          We purified from porcine pancreas a hypocalcemic peptide clearly distinguishable from other

18  PMCA in cerebral microvessels isolated from hypocalcemic rats was 150% greater than that in controls

19 dney of vitamin D-replete sham-TPTX rats and hypocalcemic TPTX rats.

20 nal CYP27B1 mRNA only in vitamin D-deficient hypocalcemic TPTX rats.

21 ts and normocalcemic TPTX rats, but not into hypocalcemic TPTX rats.